This trial is designed to see if adding ralinepag to standard PAH care or PAH-specific background therapy can improve outcomes for people with WHO Group 1 PAH.
- Pulmonary Arterial Hypertension (PAH)
- Severe Pulmonary Arterial Hypertension
- Pulmonary Arterial Hypertension
- Systemic Sclerosis-Associated Pulmonary Arterial Hypertension
- Pulmonary Hypertension
- Familial Primary Pulmonary Hypertension
- Vascular Disease
- Pulmonary Arterial Hypertension Exacerbation
- Connective Tissue Disease
- Lung Disease
- Pulmonary Arterial Hypertension of Congenital Heart Disease
- Connective Tissue Disease-Associated Pulmonary Arterial Hypertension
- Pulmonary Arterial Hypertension Gene Expression
- Cardiovascular Disease
- High Blood Pressure
- Respiratory Diseases
1 Primary · 11 Secondary · Reporting Duration: The study duration was event-based. This parameter was assessed from randomization until the conclusion of the study, up to 3 years
Side Effects for
Awards & Highlights
2 Treatment Groups
1 of 2
1 of 2
1000 Total Participants · 2 Treatment Groups
Primary Treatment: Ralinepag · Has Placebo Group · Phase 3
Who is running the clinical trial?
Age 18 - 75 · All Participants · 1 Total Inclusion CriteriaMark “Yes” if the following statements are true for you:
Who else is applying?
What state do they live in?
How old are they?
|18 - 65||100.0%|
What site did they apply to?
|University of Miami||50.0%|
|Memorial Hermann Hospital||50.0%|
What portion of applicants met pre-screening criteria?
|Did not meet criteria||100.0%|
How many prior treatments have patients received?
Frequently Asked Questions
What are some other studies that have been done using Ralinepag?
"3 trials for Ralinepag are ongoing, with the majority being Phase 3 studies. The town of Leuven in Belgium has the most clinical studies for this treatment, but 425 locations worldwide are running trials." - Anonymous Online Contributor
Are recruitment efforts for this trial focused on individuals above the age of 20?
"This study is looking for individuals who are over the age of 18 and under the age of 75." - Anonymous Online Contributor
Has Ralinepag undergone the FDA's regulatory process?
"There is data from previous phases of clinical trials and multiple rounds of safety testing that suggest Ralinepag is a safe medication, so it received a score of 3." - Anonymous Online Contributor
Might I be a compatible candidate for this research?
"The study's aim is to treat respiratory tract diseases in patients between the ages of 18 and 75. A total of 700 individuals are needed for the trial." - Anonymous Online Contributor